Scholar Rock Reports First Quarter 2023 Financial Results an

- Enrollment of pivotal Phase 3 SAPPHIRE trial evaluating apitegromab on track for completion in 2023


- Upcoming presentations of 36-month apitegromab data from Phase 2 TOPAZ trial at Cure... | May 9, 2023

Related Keywords

Florida , United States , Orlando , Ted Myles , Jay Backstrom , Richard Brudnick , Muscular Dystrophy Association , Exchange Commission , Scholar Rock Inc , Research Clinical Conference , Twitter , Scholar Rock Holding Corporation , Linkedin , Scholar Rock , Chief Executive Officer , Company Highlights , Clinical Conference , Dystrophy Association , Scientific Conference , European Society , Medical Oncology Targeted Anticancer Therapies , Chief Operating Officer , Chief Financial Officer , Securities Act , Private Securities Litigation Reform Act , Quarterly Report , Consolidated Statements , Months Ended March , Scholar Rock Holding Corporation Stock Exchange , News , Information , Press Release , Enrollment , F , Pivotal , Hase , , Sapphire , Trial , Valuating , Pitegromab , N , Track , Or , Completion , Pcoming , Presentations , Data , Rom , Topaz , T Srrk Us80706p1030 ,